Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVNNASDAQ:CALTNASDAQ:TLMDNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$9.03+8.8%$17.97$7.91▼$46.51$621.01M1.951.61 million shs8.09 million shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/ATLMDSOC Telemed$3.00$2.98$0.55▼$8.00$302.52M-1.441.28 million shsN/ATNDMTandem Diabetes Care$18.77+4.9%$32.09$17.64▼$53.69$1.25B1.451.47 million shs1.97 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+8.80%-48.40%-52.40%-54.26%-80.15%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+81.90%TLMDSOC Telemed0.00%0.00%0.00%0.00%0.00%TNDMTandem Diabetes Care+4.92%-1.78%-46.72%-45.29%-37.25%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARVNArvinas2.9674 of 5 stars4.41.00.00.02.12.50.6CALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ATLMDSOC TelemedN/AN/AN/AN/AN/AN/AN/AN/ATNDMTandem Diabetes Care4.4834 of 5 stars4.31.00.04.93.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.79Moderate Buy$43.08377.04% UpsideCALTCalliditas Therapeutics AB (publ) 2.00Hold$39.25-1.88% DownsideTLMDSOC Telemed 0.00N/AN/AN/ATNDMTandem Diabetes Care 2.61Moderate Buy$45.38141.74% UpsideCurrent Analyst Ratings BreakdownLatest TLMD, ARVN, TNDM, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025ARVNArvinasBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$82.00 ➝ $20.003/12/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$60.00 ➝ $26.003/12/2025ARVNArvinasBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$54.00 ➝ $28.003/12/2025ARVNArvinasWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$57.00 ➝ $12.003/11/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.00 ➝ $81.003/11/2025ARVNArvinasOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/7/2025ARVNArvinasCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$28.00 ➝ $19.003/5/2025TNDMTandem Diabetes CareMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$45.00 ➝ $22.003/4/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $24.003/3/2025TNDMTandem Diabetes CareThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$42.00 ➝ $24.003/3/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $22.00(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$263.40M2.36N/AN/A$8.17 per share1.11CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74TLMDSOC Telemed$94.44M3.20N/AN/A$1.66 per share1.81TNDMTandem Diabetes Care$940.20M1.33N/AN/A$4.81 per share3.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$198.90M-$2.77N/AN/AN/A-75.51%-33.75%-16.75%5/6/2025 (Estimated)CALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ATLMDSOC Telemed-$50.54M-$0.57N/A∞N/A-53.52%-34.32%-20.96%N/ATNDMTandem Diabetes Care-$222.61M-$1.46N/AN/AN/A-14.84%-44.19%-11.99%5/1/2025 (Estimated)Latest TLMD, ARVN, TNDM, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/11/2025Q4 2024ARVNArvinas-$1.07-$0.63+$0.44-$0.63$62.79 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ATLMDSOC TelemedN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A4.644.64CALTCalliditas Therapeutics AB (publ)9.442.692.59TLMDSOC Telemed0.523.323.28TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%CALTCalliditas Therapeutics AB (publ)2.83%TLMDSOC TelemedN/ATNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas5.23%CALTCalliditas Therapeutics AB (publ)2.20%TLMDSOC Telemed6.90%TNDMTandem Diabetes Care2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42068.77 million65.18 millionOptionableCALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableTLMDSOC Telemed226100.84 million93.88 millionOptionableTNDMTandem Diabetes Care2,40066.47 million64.23 millionOptionableTLMD, ARVN, TNDM, and CALT HeadlinesRecent News About These CompaniesOptimistic Buy Rating for Tandem Diabetes Care Amid Attractive Valuation and Growth PotentialMarch 13 at 2:33 AM | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Trading Up 6.1% Following Insider Buying ActivityMarch 13 at 1:56 AM | americanbankingnews.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Acquires $190,948.56 in StockMarch 12 at 7:28 PM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) COO Buys $190,948.56 in StockMarch 12 at 5:57 AM | insidertrades.comVictory Capital Management Inc. Decreases Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)March 12 at 3:34 AM | marketbeat.comTandem Diabetes COO buys $191K in common stockMarch 11 at 11:28 PM | markets.businessinsider.comReasons to Hold TNDM Stock in Your Portfolio for NowMarch 11 at 9:46 AM | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Reaches New 52-Week Low - What's Next?March 11 at 4:26 AM | marketbeat.comTandem Diabetes Care: A Buy Rating Backed by Growth Potential and Valuation OpportunityMarch 10 at 9:38 AM | tipranks.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Oppenheimer & Co. Inc.March 9, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Cut to Equal Weight at Morgan StanleyMarch 8, 2025 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Cut to "Equal Weight" at Morgan StanleyMarch 6, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Cut to "Neutral" at CitigroupMarch 6, 2025 | americanbankingnews.comMorgan Stanley Downgrades Tandem Diabetes Care (TNDM)March 6, 2025 | msn.comTandem Diabetes downgraded to Equal Weight from Overweight at Morgan StanleyMarch 5, 2025 | markets.businessinsider.comTandem Diabetes Care (NASDAQ:TNDM) Hits New 1-Year Low - Here's What HappenedMarch 5, 2025 | marketbeat.comThe Goldman Sachs Group Has Lowered Expectations for Tandem Diabetes Care (NASDAQ:TNDM) Stock PriceMarch 5, 2025 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 5.5% After Analyst DowngradeMarch 5, 2025 | americanbankingnews.comBernstein downgrades Tandem Diabetes on market share loss concernsMarch 4, 2025 | finance.yahoo.comTandem Diabetes downgraded to Neutral from Buy at CitiMarch 4, 2025 | markets.businessinsider.comTandem Diabetes Care (NASDAQ:TNDM) Downgraded by Citigroup to "Neutral"March 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLMD, ARVN, TNDM, and CALT Company DescriptionsArvinas NASDAQ:ARVN$9.03 +0.73 (+8.80%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$9.06 +0.04 (+0.39%) As of 03/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 03/11/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.SOC Telemed NASDAQ:TLMDSOC Telemed, Inc. provides acute care telemedicine services and technology to hospitals, health systems, physician groups, and government organizations in the United States. The company's Telemed IQ, a cloud-based software platform provides telemedicine solutions. Its telemedicine solutions include teleNeurology, telePulmonology, telePsychiatry, telecardiology, teleCritical Care (ICU), and other specialties. The company was founded in 2004 and is based in Herndon, Virginia. As of April 6, 2022, SOC Telemed, Inc. was taken private.Tandem Diabetes Care NASDAQ:TNDM$18.77 +0.88 (+4.92%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$18.52 -0.25 (-1.34%) As of 03/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
